Early biological signals at two distinct scales of surveillance
Dengue in wild-caught mosquitoes and tumour DNA in blood after surgery flag circulating infection and possible recurrence, each within a different evidentiary boundary.
Science··Midday
Mosquito pools captured dengue circulation in the region
In Kimpese, in the Democratic Republic of Congo near the Angola border, researchers examined 155 Aedes mosquitoes collected at three sites and combined into eight pools. Metagenomic and targeted sequencing produced high-confidence dengue reads in six of the eight pools, while evidence of human blood meals appeared in all eight. The team interprets that combination as strong evidence of endemic dengue transmission along the border. Sampling followed recent chikungunya and yellow-fever outbreaks in the country's southwest, where surveillance of mosquito-borne viruses had lagged behind malaria work. The pools also carried a diverse virome that included other known and suspected human and animal viruses. The authors present this as a case for xenosurveillance: genetic material left by what wild mosquitoes have fed on can offer an early view of pathogens circulating among people. Pooled field samples provide an alert about regional circulation, within a geographical and sampling scope distinct from individual diagnosis. This regional measurement leaves the identity of ill people and the number of infections represented by each positive pool undetermined.[1]
Tumour DNA in blood flagged recurrence earlier
A molecular residual disease analysis of the phase 3 EVIDENCE trial used 1,352 plasma samples from 175 patients with resected stage II–IIIA EGFR-mutated non-small cell lung cancer. A positive result based on circulating tumour DNA in blood preceded recurrence seen on imaging by a median of 169 days. At the landmark timepoint, positivity was 35.8 per cent among stage III patients and 14.7 per cent among stage II patients. Positivity tracked worse disease-free survival, with a reported hazard ratio of 4.44 at landmark and 7.82 during longitudinal monitoring. Serial testing with the tumour-informed MinerVa Prime assay had a negative predictive value of 91.3 per cent and a longitudinal positivity rate of 47.4 per cent; the measurement 24 weeks after randomisation carried the most prognostic weight. These results come from a defined clinical-trial group. The positive DNA signal was associated with elevated recurrence risk and may provide an earlier warning of possible recurrence. Its scope is limited to risk prediction; disease location on imaging and whether recurrence will occur in every positive patient remain unresolved. A negative result offers confidence only within the reported predictive value.[2]
The sampling unit determines what an early signal means
Both studies look in biological material for a signal that emerges before direct observation. Their units of surveillance are entirely different. The Kimpese mosquito pools capture dengue genetic material in vectors that had fed on people, making circulation visible in a particular border region. The EVIDENCE analysis searches each patient's plasma over time for tumour-informed DNA after diagnosis and surgery in people whose cancers carry an EGFR mutation. The first is a regional signal that may inform public-health surveillance; the second is an individual risk marker tied to clinical follow-up in a defined patient group. That distinction prevents the two positive results from saying the same thing. A dengue read in a mosquito is evidence of regional circulation, outside the scope of individual diagnosis. Tumour DNA in blood marks recurrence risk in defined patients, outside the scope of population cancer prevalence. Their shared value lies in the possibility of gaining time: one brings forward circulation missed by field surveillance, and the other brings forward a molecular recurrence signal that can precede imaging. In each case, meaning depends on where the sample came from, how it was grouped and what comparison supports its interpretation.[1], [2]
